Compare KeyCorp (KEY) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Vaxcyte Inc. Common Stock — how do they compare? KeyCorp trades at $19.83 (market cap $21.25B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: KeyCorp is far larger — about 2× Vaxcyte Inc. Common Stock's market cap, and KeyCorp pays a 4.12% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KEY | PCVX | |
|---|---|---|
Market Cap | $21.25B | $10.51B |
Volume | 17,676,934 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $23.99 | $73.82 |
52-Week Low | $16.78 | $40.32 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $34.43B | $9.14B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.79, down 1.49% on the day, with a bearish technical signal but strong fundamentals including a P/E of 11.64 and net income margin of 26.72%. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.21 dividend. Analyst consensus is bullish with a $25.00 price target, though recent news highlights competitive dividend pressures.
The outlook for KEY is positive based on earnings momentum and valuation, but risks include interest rate sensitivity and frozen dividends. Upside potential exists if loan growth and fee income continue to drive revenue, yet investor sentiment is cautious amid technical weakness and macroeconomic uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
